Researchers identified CLDN6 as a driver of colorectal cancer liver metastasis in aggressive consensus molecular subtype 4 (CMS4), using multi-omics datasets and preclinical models. The work tied CLDN6 to distinct signaling and epigenetic reprogramming associated with metastatic spread, framing it as a potential surface marker and mechanistic lever within CMS4 biology. The study positions CLDN6 as a candidate target for further functional work and therapeutic exploration in metastatic settings where CMS4 is enriched, particularly in liver-homing phenotypes. By linking patient data to preclinical validation, the findings move beyond correlation toward hypothesis-driven target biology.
Get the Daily Brief